Addressing Unmet Medical Needs in Type 1 Diabetes: A Review of Drugs Under Development

Overview

Journal Curr Diabetes Rev

Publisher Bentham Science Publishers

Specialty Endocrinology

Date 2016 Apr 14

PMID 27071617

Citations 5

Authors

Friedrich Mittermayer

Erica Caveney

Claudia de Oliveira

G Alexander Fleming

Loukas Gourgiotis

Mala Puri

Li-Jung Tai

J Rick Turner

Affiliations

Soon will be listed here.

Abstract

The incidence of type 1 diabetes (T1D) is increasing worldwide and there is a very large need for effective therapies. Essentially no therapies other than insulin are currently approved for the treatment of T1D. Drugs already in use for type 2 diabetes and many new drugs are under clinical development for T1D, including compounds with both established and new mechanisms of action. Content of the Review: Most of the new compounds in clinical development are currently in Phase 1 and 2. Drug classes discussed in this review include new insulins, SGLT inhibitors, GLP-1 agonists, immunomodulatory drugs including autoantigens and anti-cytokines, agents that regenerate β-cells and others. Regulatory Considerations: In addition, considerations are provided with regard to the regulatory environment for the clinical development of drugs for T1D, with a focus on the United States Food and Drug Administration and the European Medicines Agency. Future opportunities, such as combination treatments of immunomodulatory and beta-cell regenerating therapies, are also discussed.

Citing Articles

First-in-human, double-blind, randomized phase 1b study of peptide immunotherapy IMCY-0098 in new-onset type 1 diabetes.

van Rampelbergh J, Achenbach P, Leslie R, Ali M, Dayan C, Keymeulen B BMC Med. 2023; 21(1):190.

PMID: 37226224 PMC: 10210318. DOI: 10.1186/s12916-023-02900-z.

Antimicrobial protein REG3A regulates glucose homeostasis and insulin resistance in obese diabetic mice.

Gonzalez P, Dos Santos A, Darnaud M, Moniaux N, Rapoud D, Lacoste C Commun Biol. 2023; 6(1):269.

PMID: 36918710 PMC: 10015038. DOI: 10.1038/s42003-023-04616-5.

Ceramide Synthases Are Attractive Drug Targets for Treating Metabolic Diseases.

Raichur S Front Endocrinol (Lausanne). 2020; 11:483.

PMID: 32849276 PMC: 7403459. DOI: 10.3389/fendo.2020.00483.

Dapagliflozin: A Review in Type 1 Diabetes.

Paik J, Blair H Drugs. 2019; 79(17):1877-1884.

PMID: 31664708 PMC: 6881422. DOI: 10.1007/s40265-019-01213-x.

Selectivity, cell permeability and oral availability studies of novel bromophenol derivative HPN as protein tyrosine phosphatase 1B inhibitor.

Luo J, Xu Q, Jiang B, Zhang R, Jia X, Li X Br J Pharmacol. 2017; 175(1):140-153.

PMID: 29059712 PMC: 5740242. DOI: 10.1111/bph.14080.

References

Tikkanen I, Narko K, Zeller C, Green A, Salsali A, Broedl U . Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care. 2014; 38(3):420-8. DOI: 10.2337/dc14-1096. View

Rother K, Spain L, Wesley R, Digon 3rd B, Baron A, Chen K . Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes. Diabetes Care. 2009; 32(12):2251-7. PMC: 2782986. DOI: 10.2337/dc09-0773. View

Fourlanos S, Dotta F, Greenbaum C, Palmer J, Rolandsson O, Colman P . Latent autoimmune diabetes in adults (LADA) should be less latent. Diabetologia. 2005; 48(11):2206-12. DOI: 10.1007/s00125-005-1960-7. View

Palmer J, Fleming G, Greenbaum C, Herold K, Jansa L, Kolb H . C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes. 2003; 53(1):250-64. DOI: 10.2337/diabetes.53.1.250. View

Seaquist E, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L . Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013; 36(5):1384-95. PMC: 3631867. DOI: 10.2337/dc12-2480. View

Keymeulen B, Walter M, Mathieu C, Kaufman L, Gorus F, Hilbrands R . Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia. 2010; 53(4):614-23. DOI: 10.1007/s00125-009-1644-9. View

Creusot R, Giannoukakis N, Trucco M, Clare-Salzler M, Fathman C . It's time to bring dendritic cell therapy to type 1 diabetes. Diabetes. 2013; 63(1):20-30. PMC: 3968436. DOI: 10.2337/db13-0886. View

Parikh A, Stephan A, Tzanakakis E . Regenerating proteins and their expression, regulation and signaling. Biomol Concepts. 2012; 3(1):57-70. PMC: 3348543. DOI: 10.1515/bmc.2011.055. View

Gitelman S, Gottlieb P, Rigby M, Felner E, Willi S, Fisher L . Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2014; 1(4):306-16. PMC: 6489466. DOI: 10.1016/S2213-8587(13)70065-2. View

10.

Eldor R, Arbit E, Corcos A, Kidron M . Glucose-reducing effect of the ORMD-0801 oral insulin preparation in patients with uncontrolled type 1 diabetes: a pilot study. PLoS One. 2013; 8(4):e59524. PMC: 3622027. DOI: 10.1371/journal.pone.0059524. View

11.

Nathan D, Genuth S, Lachin J, Cleary P, Crofford O, Davis M . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329(14):977-86. DOI: 10.1056/NEJM199309303291401. View

12.

Kuhadiya N, Malik R, Bellini N, Patterson J, Traina A, Makdissi A . Liraglutide as additional treatment to insulin in obese patients with type 1 diabetes mellitus. Endocr Pract. 2013; 19(6):963-7. DOI: 10.4158/EP13065.OR. View

13.

Zinman B, Lachin J, Inzucchi S . Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2016; 374(11):1094. DOI: 10.1056/NEJMc1600827. View

14.

Hagopian W, Ferry Jr R, Sherry N, Carlin D, Bonvini E, Johnson S . Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial. Diabetes. 2013; 62(11):3901-8. PMC: 3806608. DOI: 10.2337/db13-0236. View

15.

Wild D, von Maltzahn R, Brohan E, Christensen T, Clauson P, Gonder-Frederick L . A critical review of the literature on fear of hypoglycemia in diabetes: Implications for diabetes management and patient education. Patient Educ Couns. 2007; 68(1):10-5. DOI: 10.1016/j.pec.2007.05.003. View

16.

Skyler J, Ricordi C . Stopping type 1 diabetes: attempts to prevent or cure type 1 diabetes in man. Diabetes. 2011; 60(1):1-8. PMC: 3012160. DOI: 10.2337/db10-1114. View

17.

Haller M, Gitelman S, Gottlieb P, Michels A, Rosenthal S, Shuster J . Anti-thymocyte globulin/G-CSF treatment preserves β cell function in patients with established type 1 diabetes. J Clin Invest. 2014; 125(1):448-55. PMC: 4382237. DOI: 10.1172/JCI78492. View

18.

Skyler J, Krischer J, Wolfsdorf J, Cowie C, Palmer J, Greenbaum C . Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1. Diabetes Care. 2005; 28(5):1068-76. DOI: 10.2337/diacare.28.5.1068. View

19.

Lewis E . Expanding the clinical indications for α(1)-antitrypsin therapy. Mol Med. 2012; 18:957-70. PMC: 3459478. DOI: 10.2119/molmed.2011.00196. View

20.

Livingstone S, Levin D, Looker H, Lindsay R, Wild S, Joss N . Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008-2010. JAMA. 2015; 313(1):37-44. PMC: 4426486. DOI: 10.1001/jama.2014.16425. View